| Description |
1 online resource (1 volume). |
| Physical Medium |
polychrome |
| Description |
text file |
| Series |
Drug discovery series ;
no. 68, 2041-3203
|
|
RSC drug discovery series ; 68.
2041-3203
|
| Bibliography |
Includes bibliographical references and index. |
| Contents |
Intro; Half Title; Series Editors; Title; Copyright; Foreword; Preface; Contents; Chapter 1 History and Development of Nucleotide Analogues in Nucleic Acids Drugs 1; 1.1 Introduction; 1.2 The Antisense Concept; 1.3 Developments in Oligonucleotide Synthesis; 1.4 Choices for Antisense Oligodeoxynucleotide Modifications; 1.4.1 Backbone Modifications; 1.4.2 Heterocyclic Bases; 1.4.3 Sugar Modifications; 1.5 Gapmers Using Combinations of Modified Oligodeoxy and/or Oligoribonucleotides; 1.6 Antisense Conjugates; 1.7 The Role of Innate Immune Receptors in Nucleic Acid Therapeutics |
|
1.8 Future DirectionsAcknowledgements; References; Chapter 2 Mechanisms of Antisense Oligonucleotides 22; 2.1 Introduction; 2.2 RNase H and ASO Action; 2.3 ASOs and Regulation of Splicing; 2.4 ASOs and Activation of Frataxin, a Case Study for an Emerging Mechanism; 2.5 Summary; Acknowledgements; References; Chapter 3 The Medicinal Chemistry of RNase H-activating Antisense Oligonucleotides 32; 3.1 Introduction to Gapmers; 3.2 Human RNase H1; 3.2.1 Biochemistry of Human RNase H1; 3.2.2 Structural Biology of Human RNase H1; 3.3 Structure-Activity Relationships of Gap Modifications |
|
3.5.4 ASO Gapmer Duplexes3.6 Control of Protein Binding; 3.6.1 Interaction of Gapmer ASOs with Plasma Proteins; 3.6.2 Interaction of Gapmer-ASOs with Cell-surface Proteins; 3.6.3 Targeting Cell-surface Proteins for Cell-specific Delivery of Gapmers; 3.6.4 Avoiding Interactions with TLR Receptors to Avoid Immune-stimulatory Toxicities; 3.6.5 Optimizing Intracellular Distribution; 3.7 Conclusions; References; Chapter 4 Antisense Technology: Liver Targeting and Beyond for Drug Discovery 62; 4.1 Introduction; 4.2 Liver Targeting; 4.2.1 The Beginning; 4.2.2 Broadening the Liver-targeting Pipeline |
|
4.3 Innovations in Liver Targeting4.4 Beyond the Liver; 4.5 Conclusions; References; Chapter 5 Oligonucleotide-based Toll-like Receptor Antagonists and Therapeutic Applications 80; 5.1 Introduction; 5.2 Oligonucleotide-based TLR Antagonists; 5.2.1 Structure-Activity Relationship Studies; 5.2.2 TLR Antagonists; 5.2.3 Inhibitory Activity of TLR Antagonists; 5.2.4 Inhibitory Activity of Clinical Candidates; 5.3 Studies of TLR Antagonists in Disease Models; 5.3.1 Psoriasis; 5.3.2 Systemic Lupus Erythematosus (SLE); 5.3.3 Rheumatoid Arthritis (RA); 5.3.4 Duchenne Muscular Dystrophy (DMD) |
| Summary |
Advances in Nucleic Acid Therapeutics provides a broad overview of techniques of contemporary interest in drug discovery. |
| Local Note |
eBooks on EBSCOhost EBSCO eBook Subscription Academic Collection - North America |
| Subject |
Nucleic acids -- Therapeutic use.
|
|
Nucleic acids -- Therapeutic use. |
|
Nucleic acids. |
| Genre/Form |
Electronic books.
|
| Added Author |
Agrawal, Sudhir, editor.
|
|
Gait, M. J. (Michael J.), editor.
|
|
Royal Society of Chemistry (Great Britain), issuing body.
|
| Other Form: |
Print version: ADVANCES IN NUCLEIC ACID THERAPEUTICS. [Place of publication not identified], ROYAL Society OF CHEMISTR, 2019 1788012097 (OCoLC)1036274247 |
| ISBN |
9781788017329 (electronic book) |
|
1788017323 (electronic book) |
|
1788012097 |
|
9781788012096 |
|
9781788015714 (PDF ebook) |
|
1788015711 |
|
